Genetic Technologies tanks as CEO resigns in protest over board spill
Wednesday, 28 November, 2012
Genetic Technologies (ASX:GTG) has shed over a quarter of its share value following the resignation of its CEO Paul MacLeman a yesterday’s annual general meeting.
MacLeman’s resignation came in protest after noted biotech entrepreneur Mel Bridges and Huw Jones were dumped from the board by shareholders.
The Australian is reporting that GTG founder, and major shareholder, Mervyn Jacobson, hefted his 29 per cent stake behind the “no” vote against Bridges and Jones.
Following the vote was a string of resignations, including CEO Dr Paul MacLeman, VP Legal and Corporate Development Dr David Sparling and fellow board member, Greg Brown.
Mal Brandon has been appointed the chairman of the board, and COO Alison Mew has taken over as Acting CEO.
Following the spill, Bridges said “it is regrettable that a company with the potential of GTG was unable to reach middle ground with its major shareholder.”
During the AGM the company also announced it has a database of 1700 companies it believes it is infringing on its intellectual property, and that as a consequence, it anticipates “many more years of available licensing”.
GTG shared were trading at 8.7 cents yesterday but plummeted 29% to 6.2 cents as of around 1pm Wednesday.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
